Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | RAB9A | P51151 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31587825 | 0.89 | MAPT (1.00) | MAPTRAB9AALDH1A1SMN1; SMN2S1PR1 | |
| SCHEMBL23851060 | 0.89 | MAPT (1.00) | MAPTRAB9AALDH1A1SMN1; SMN2S1PR1 | |
| SCHEMBL17479658 | 0.79 | RAB9A (0.51) | MAPTRAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL15956987 | 0.77 | LMNA (0.61) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1666590 | 0.77 | MAPT (0.55) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL1028539 | 0.77 | SMN1; SMN2 (0.67) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL259406 | 0.77 | MAPT (0.69) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2727254 | 0.75 | MAPT (0.47) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL17479770 | 0.75 | MAPT (0.48) | MAPTRAB9AALDH1A1KMT2AKDM4E | |
| SCHEMBL22130110 | 0.73 | MAPT (0.55) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | MAPT 4682/4885RAB9A 1131/4885ALDH1A1 342/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MAPT 4682/4885RAB9A 1131/4885ALDH1A1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.